Recruitment Messages for Current Smokers Recently Diagnosed With Cancer
20. Juli 2022 aktualisiert von: University of Oklahoma
A Multimethod Evaluation of Tobacco Treatment Trial Recruitment Messages for Current Smokers Recently Diagnosed With Cancer: Pilot Factorial Randomized Controlled Trial
The objective of this study was to conduct a pilot factorial randomized trial to identify the message frames that are most effective in promoting participation in a tobacco treatment trial for current smokers recently diagnosed with cancer.
To do so, we used a multimethod approach to evaluate 3 different message frames across evaluation, effectiveness, and outcome measures.
We combine findings from a message design experiment with textual analytic software to provide a holistic understanding of how message frames may or may not differentially affect tobacco treatment trial participation within the context of a cancer diagnosis.
Studienübersicht
Status
Abgeschlossen
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Background: A cancer diagnosis can catalyze motivation to quit smoking. Tobacco treatment trials offer cessation resources but have low accrual rates. Digital outreach may improve accrual, but knowledge of how best to recruit smokers with recent diagnoses is limited.
Objective: This study aims to identify the message frames that were most effective in promoting intent to talk to a physician about participating in a tobacco treatment trial for smokers recently diagnosed with cancer.
Methods: From February to April 2019, current smokers diagnosed within the past 24 months were recruited from a national web-based panel for a multimethod pilot randomized trial (N=99). Participants were randomized to a 2×3 plus control factorial design that tested 3 unique message frames: proximal versus distal threats of smoking, costs of continued smoking versus benefits of quitting, and gains of participating versus losses of not participating in a tobacco treatment trial.
Studientyp
Interventionell
Einschreibung (Tatsächlich)
99
Phase
- Unzutreffend
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienorte
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Vereinigte Staaten, 73104
- Jordan Neil
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
18 Jahre und älter (Erwachsene, Älterer Erwachsener)
Akzeptiert gesunde Freiwillige
Ja
Studienberechtigte Geschlechter
Alle
Beschreibung
Inclusion Criteria:
- Speak and understand English
- A recent cancer diagnosis (within the past 24 months)
- 18 years or older
- Report any cigarette use within the past 30 days
Exclusion Criteria:
- Do not speak or understand English
- Have not been diagnosed with cancer within the past 24 months
- Below the age of 18
- Does not report any cigarette use within the past 30 days
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Unterstützende Pflege
- Zuteilung: Zufällig
- Interventionsmodell: Fakultätszuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Schein-Komparator: Control
The control condition was a kernel message that included study information present in all conditions but did not include any of the message factors.
|
Does not include any of the three message factors.
|
|
Experimental: Proximal x Cost x Loss
Message frame: proximal threats of smoking, cost of continued smoking, and loss of not participating in a tobacco treatment trial.
|
The first factor tested framing of the near, proximal threat of continued smoking.
Cost framework measures the response efficacy to quitting smoking by displaying costs of continued smoking.
The third factor tested framing of the response efficacy of participating in a cessation study by utilizing loss of not participating in a smoking cessation.
|
|
Experimental: Proximal x Cost x Gain
Message frame: proximal threats of smoking, cost of continued smoking, and gain of participating in a tobacco treatment trial.
|
The first factor tested framing of the near, proximal threat of continued smoking.
Cost framework measures the response efficacy to quitting smoking by displaying costs of continued smoking.
The third factor tested framing of the response efficacy of participating in a cessation study by utilizing gain of participating in a smoking cessation.
|
|
Experimental: Proximal x Benefit x Gain
Message frame: proximal threats of smoking, benefits of quitting, and gain of participating in a tobacco treatment trial.
|
The first factor tested framing of the near, proximal threat of continued smoking.
The third factor tested framing of the response efficacy of participating in a cessation study by utilizing gain of participating in a smoking cessation.
Benefit framework measures the response efficacy to quitting smoking by displaying benefits of quitting.
|
|
Experimental: Proximal x Benefit x Loss
Message frame: proximal threats of smoking, benefits of quitting, and loss of not participating in a tobacco treatment trial.
|
The first factor tested framing of the near, proximal threat of continued smoking.
The third factor tested framing of the response efficacy of participating in a cessation study by utilizing loss of not participating in a smoking cessation.
Benefit framework measures the response efficacy to quitting smoking by displaying benefits of quitting.
|
|
Experimental: Distal x Cost x Gain
Message frame: distal threats of smoking, cost of continued smoking, and gain of participating in a tobacco treatment trial.
|
Cost framework measures the response efficacy to quitting smoking by displaying costs of continued smoking.
The third factor tested framing of the response efficacy of participating in a cessation study by utilizing gain of participating in a smoking cessation.
The first factor tested framing of the long-term, distal threat of continued smoking.
|
|
Experimental: Distal x Cost x Loss
Message frame: distal threats of smoking, cost of continued smoking, and loss of not participating in a tobacco treatment trial.
|
Cost framework measures the response efficacy to quitting smoking by displaying costs of continued smoking.
The third factor tested framing of the response efficacy of participating in a cessation study by utilizing loss of not participating in a smoking cessation.
The first factor tested framing of the long-term, distal threat of continued smoking.
|
|
Experimental: Distal x Benefit x Loss
Message frame: distal threats of smoking, benefits of quitting, and loss of not participating in a tobacco treatment trial.
|
The third factor tested framing of the response efficacy of participating in a cessation study by utilizing loss of not participating in a smoking cessation.
Benefit framework measures the response efficacy to quitting smoking by displaying benefits of quitting.
The first factor tested framing of the long-term, distal threat of continued smoking.
|
|
Experimental: Distal x Benefit x Gain
Message frame: distal threats of smoking, benefits of quitting, and gain of participating in a tobacco treatment trial.
|
The third factor tested framing of the response efficacy of participating in a cessation study by utilizing gain of participating in a smoking cessation.
Benefit framework measures the response efficacy to quitting smoking by displaying benefits of quitting.
The first factor tested framing of the long-term, distal threat of continued smoking.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Difference in intent to talk to a physician about participating in a smoking cessation study between factors.
Zeitfenster: Within 30 minutes
|
The main effect within each message factor level was examined using ANOVA and compared with the control condition.
|
Within 30 minutes
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Predictors of intent to talk to a physician about participating in a smoking cessation study.
Zeitfenster: Within 30 minutes
|
Other message evaluation and effectiveness measures were collected and explored in a multivariable model predicting intent to talk to a physician.
|
Within 30 minutes
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Ermittler
- Hauptermittler: Jordan Neil, Ph.D., TSET Health Promotion Research Center
Publikationen und hilfreiche Links
Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Tatsächlich)
11. Februar 2019
Primärer Abschluss (Tatsächlich)
1. April 2019
Studienabschluss (Tatsächlich)
2. April 2019
Studienanmeldedaten
Zuerst eingereicht
13. Juli 2022
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
20. Juli 2022
Zuerst gepostet (Tatsächlich)
22. Juli 2022
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
22. Juli 2022
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
20. Juli 2022
Zuletzt verifiziert
1. Juli 2022
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Andere Studien-ID-Nummern
- 2018P002035
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
NEIN
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Nein
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Nein
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .